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Abstract
Brucellosis is a bacterial zoonosis and a significant source of economic loss and a major public health concern,
worldwide. Bovine brucellosis, as caused primarily by Brucella abortus, is an important cause of reproductive
loss in cattle. Vaccination has been the most effective way to reduce disease prevalence contributing to the
success of control and eradication programs. Currently, there are no human vaccines available, and despite the
success of commercial vaccines for livestock, such as B. abortus strain RB51 (RB51), there is need for
development of novel and safer vaccines against brucellosis. In the current study, we report the fabrication of
and immune responses to an implantable single dose polyanhydride-based, methanol-killed RB51 antigen
containing delivery platform (VPEAR) in cattle. In contrast to animals vaccinated with RB51, we did not
observe measurable RB51-specific IFN-γ or IgG responses in the peripheral blood, following initial
vaccination with VPEAR. However, following a subsequent booster vaccination with RB51, we observed an
anamnestic response in both vaccination treatments (VPEAR and live RB51). The magnitude and kinetics of
CD4+ IFN-γ-mediated responses and circulating memory T cell subpopulations were comparable between
the two vaccination treatments. Additionally, IgG titers were significantly increased in animals vaccinated with
VPEAR as compared to live RB51- vaccinated animals. These data demonstrate that killed antigen may be
utilized to generate and sustain memory, IFN-γ-mediated, CD4+ T cell and humoral responses against
Brucella in a natural host. To our knowledge, this novel approach to vaccination against intracellular bacteria,
such as Brucella, has not been reported before.
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A B S T R A C T
Brucellosis is a bacterial zoonosis and a significant source of economic loss and a major public health concern,
worldwide. Bovine brucellosis, as caused primarily by Brucella abortus, is an important cause of reproductive loss
in cattle. Vaccination has been the most effective way to reduce disease prevalence contributing to the success of
control and eradication programs. Currently, there are no human vaccines available, and despite the success of
commercial vaccines for livestock, such as B. abortus strain RB51 (RB51), there is need for development of novel
and safer vaccines against brucellosis. In the current study, we report the fabrication of and immune responses to
an implantable single dose polyanhydride-based, methanol-killed RB51 antigen containing delivery platform
(VPEAR) in cattle. In contrast to animals vaccinated with RB51, we did not observe measurable RB51-specific IFN-
γ or IgG responses in the peripheral blood, following initial vaccination with VPEAR. However, following a
subsequent booster vaccination with RB51, we observed an anamnestic response in both vaccination treatments
(VPEAR and live RB51). The magnitude and kinetics of CD4þ IFN-γ-mediated responses and circulating memory
T cell subpopulations were comparable between the two vaccination treatments. Additionally, IgG titers were
significantly increased in animals vaccinated with VPEAR as compared to live RB51- vaccinated animals. These
data demonstrate that killed antigen may be utilized to generate and sustain memory, IFN-γ-mediated, CD4þ T
cell and humoral responses against Brucella in a natural host. To our knowledge, this novel approach to vacci-
nation against intracellular bacteria, such as Brucella, has not been reported before.
1. Introduction
Brucellosis is a zoonosis caused by bacteria of the genus Brucella.
Worldwide, brucellosis is a significant source of economic losses and a
major public health concern. In humans, brucellosis can result in a
chronic debilitating disease while in domestic species (cattle, goats,
sheep) brucellosis results in infertility and reproductive losses. In cattle,
brucellosis is primarily caused by Brucella abortus and vaccination is a
major factor in the success of control and eradication programs (reviewed
in (Olsen and Stoffregen, 2005)). Commercially-available cattle vaccines
against B. abortus include RB51 and S19, however, safe and effective
vaccines for humans (and other domestic species) are currently not
available. The RB51 vaccine is a lipopolysaccharide O-antigen-deficient
rough mutant derived from B. abortus 2308, a smooth, virulent field
strain. RB51 has been demonstrated to provide long-lasting immunity
and protection against infection with field strains of B. abortus in cattle
(Cheville et al., 1996; Cheville et al., 1993; Olsen, 2000; Poester et al.,
2006). In addition, RB51 does not induce serologic responses that
interfere with brucellosis surveillance tests (Schurig et al., 1991). How-
ever, RB51 has some drawbacks. Although less virulent than other vac-
cine strains and generally safe for use in pregnant cattle (Palmer et al.,
1997), RB51 can be abortigenic (Yazdi et al., 2009). Additionally, recent
reports have shown that RB51 can be shed in milk of
previously-vaccinated cattle and infect humans through the consumption
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of unpasteurized milk (Cossaboom et al., 2018). This zoonotic potential
raises important public health concerns as the RB51 strain is resistant to
rifampicin, the antibiotic of choice for treating human brucellosis
(Marianelli et al., 2004). Due to these drawbacks and the lack of safe and
efficacious vaccines for other species, there is continued interest for
development of novel vaccines that may be used to prevent brucellosis in
animals and humans.
Brucella spp. are facultative intracellular pathogens, which reside
within macrophages and can set up long-term residence within infected
cells. Immunity against intracellular pathogens is considered to be pri-
marily mediated by T helper (TH)-1 responses, characterized by
interferon-gamma (IFN-γ)-producing CD4þ and CD8þ T cells. Live Bru-
cella vaccines have been shown to be far superior to inactivated vaccines
for protection against infection (Montaraz and Winter, 1986; Zhan et al.,
1993, 1995). Interestingly, while heat-killed preparations of Brucella can
act as TH1-promoting adjuvants (Huang et al., 1999, 2003, 2005), killed
Brucella are unable to confer protection against challenge (Zhan et al.,
1993, 1995). Moreover, both killed and live vaccines promote humoral
responses, yet only live bacteria promote the development of memory
IFN-γ-producing CD4þ T cells (Vitry et al., 2014). These data suggest that
the nature (i.e. live vs. killed antigen), as well as persistence and locali-
zation of antigen, may be key factors in promoting protective immunity
against Brucella infection.
Concomitant immunity, or non-sterile immunity, is characterized by
the ability of a host to mount an effective immune response against an
organism without resulting in its complete clearance (Coffman et al.,
2010; Perignon and Druilhe, 1994; Smith et al., 1999). Leishmania major
and Plasmodium falciparum are both examples of organisms that promote
concomitant immunity. During L. major infection, small numbers of
parasites remain within the original site of infection and the draining
lymph node (Nicolas et al., 2000). Resulting concomitant immunity is
driven by a small pool of replicating parasites, from which some are
destroyed and serve to provide a life-long supply of antigen stimulation
to the host (Mandell and Beverley, 2017). Complete removal of these
parasites by the host immune response results in loss of immunity (Bel-
kaid et al., 2002). We hypothesize that a vaccination platform that
mimics this long-term antigen release in the presence of inflammatory
signals could generate protective and long-lived responses against
persistent intracellular pathogens, such as Brucella spp. without inducing
tolerance.
Polyanhydrides (PA) are biodegradable polymers that have been
previously shown to be safe (Huntimer et al., 2013; Vela-Ramirez et al.,
2015) and efficacious as delivery platforms for vaccine antigens (Car-
rillo-Conde et al., 2010; Petersen et al., 2009; Ross et al., 2015; Torres
et al., 2006; Ulery et al., 2011a,b). Their effectiveness is centered around
their ability to protect their payload (i.e. antigen) from degradation
(Carrillo-Conde et al., 2010; Haughney et al., 2013; Ross et al., 2014;
Vela Ramirez et al., 2014), their immune-enhancing nature (i.e.
pathogen-mimicking) (Ulery et al., 2011b), and the ability to modulate
antigen release by altering the degradation characteristics of the polymer
chemistry (Carrillo-Conde et al., 2010; Petersen et al., 2009; Ross et al.,
2015; Torres et al., 2006; Ulery et al., 2011a). Polyanhydride
co-polymers consisting of 1,8-bis(pcarboxyphenoxy)-3,6-dioxaoctane
(CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH), in a 20:80 ratio
(i.e. 20:80 CPTEG:CPH), have been previously assessed for their ability to
entrap proteins and for their low surface erosion properties, which allows
for continuous antigen release (Torres et al., 2006; Vela-Ramirez et al.,
2015).
In this study, we report the fabrication of an implantable single dose
20:80 CPTEG:CPH polymer-based, methanol-killed RB51 antigen-
containing vaccine platform for extended antigen release (VPEAR). The
rationale behind VPEAR is to provide the immune systemwith a three-hit
model of antigen delivery to mimic the mechanism driving concomitant
immunity: (1) a soluble component, which initially primes the immune
system, (2) a boosting dose of antigen, provided by surface erosion and
degradation of a solid polyanhydride rod over 3 months, and (3) a
sustained release of antigen over a longer period of time (within 38
months) using a solid polyanhydride rod within a polyethylene implant,
capped with a PVDF membrane (Schaut et al., 2018b). Inclusion of the
PVDF membrane (0.65 μm pore size) restricts cells from accessing the
antigen depot, yet allows antibody entry into the implant. The PVDF
membrane caps a collagen immunodiffusion barrier overlaying the an-
tigen depot, whereby the size of antigen-antibody complexes within the
immunodiffusion barrier could theoretically provide a dynamic rela-
tionship between the immune response and antigen release.
In this study we assessed and compared the peripheral CD4þ T cell
and humoral immune responses to VPEAR and RB51 following initial
vaccination and subsequent RB51 booster vaccination. Additionally, we
characterize the histologic changes occurring at the site of VPEAR
implantation.
2. Materials and methods
2.1. Polyanhydride formulations
20:80 CPTEG:CPH copolymer was synthesized using melt poly-
condensation as previously described (Torres et al., 2006). The molar
composition and number-average molecular weight was determined via
end group analysis of 1H NMR spectra (DXR 500). Thermal properties of
the polymer, including its glass transition temperature, were determined
using differential scanning calorimetry (Q2000, TA Instruments). The
20:80 CPTEG:CPH copolymer had a molar composition of 21:79 (mol
CPTEG:mol CPH), a number-average molecular weight of 6,111 g/mol,
and a glass transition temperature of 29.7 C, consistent with previous
reports (Torres et al., 2006).
2.2. Methanol-killed RB51 antigen generation
Commercially-available RB51 vaccine (Colorado Serum Company,
Denver, CO) was inoculated in Brucella broth (Becton Dickinson, Sparks,
MD). The inoculum was incubated at 37 C with constant shaking until
reaching an optical density (OD) value of 1.5, equivalent to approxi-
mately 1010 colony forming units (CFU)/mL. After inactivation in 60%
methanol for 7 days, loss of viability was confirmed by plating onto
tryptose agar plates with 5% bovine serum and incubation for 7 days at
37 C with 5% CO2. After confirmation of inactivation, methanol-killed
RB51 was centrifuged at 30,000 x g for 30 min at 4 C to remove solu-
ble media components. The pellet was resuspended in sterile, culture-
grade Dulbecco's phosphate-buffered saline (DPBS), centrifuged again,
resuspended in high-grade methanol, and stored at 4 C until use.
2.3. Rod and implant design (VPEAR)
Polyanhydride (PA) rod and implant synthesis were performed as
previously described (Schaut et al., 2018b). The rod consisted of 208 mg
of PA, 1 1010 CFU of methanol-killed RB51, and 50 μg of MPLA derived
from Salmonella minnesota R595 (InvivoGen, San Diego, CA). The rod that
was placed in the implant consisted of 138 mg of PA, 1  1010 CFU of
sonicated, methanol-killed RB51, and 50 μg of MPLA (InvivoGen).
Air-dried mixtures of all components were pressed in a custom-made
mold at 0.5 tons-on-ram for 5 s, using an International Crystal Labora-
tories hydraulic press. The implant was designed and formulated as
previously described (Schaut et al., 2018a).
2.4. Animal vaccinations
Holstein steers, 6–8 months old, were housed in field barns at the
National Animal Disease Centers (NADC) in Ames, IA. All experiments
were approved by the NADC Institutional Animal Care and Use Com-
mittee (IACUC). Upon arrival, all steers were dewormed and vaccinated
with Triangle 5 vaccine (Boehringer Ingleheim, Fort Dodge, IA). After
acclimation, animals were randomly assigned to one of three treatment
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groups: naïve (n¼ 6), live RB51 (n¼ 6), or VPEAR (n¼ 8). Naïve animals
received 2 mL of phosphate buffered saline (PBS) subcutaneously (SQ) in
the cervical region, using a 1 ½ inch 20-gauge needle. Animals in the
RB51 group were SQ vaccinated with 3  1010 colony-forming units
(CFU) of a commercial RB51 vaccine (Lot number 2639, Colorado Serum
Company) in the cervical region using a 1½ inch, 20-gauge needle. In the
VPEAR group, the implant and rod were surgically administered SQ
along with a soluble injection of 1  1010 CFU of methanol-killed RB51,
using a 1 ½ inch 20-gauge needle. Blood was collected via venipucture at
4-week intervals to track humoral and cellular responses. Booster vac-
cinations were performed at 10 months post-initial vaccination, SQ, with
3  1010 CFU of a commercial RB51 vaccine (Colorado Serum Company)
in the cervical region using a 1 ½ inch 20-gauge needle. Blood was
collected via venipuncture at 2, 4, and 8 weeks post-boost to track
cellular responses and at 4 week intervals to track humoral responses. At
the end of the study, animals were humanely euthanized via intravenous
injection of pentobarbital sodium solution.
2.5. Peripheral blood mononuclear cells (PBMC) isolation and in vitro
stimulation
PBMC were isolated from peripheral blood via Ficoll gradient sepa-
ration as previously described (Olsen et al., 2009). After assessing
numbers of viable cells by trypan blue exclusion, PBMC were plated onto
96-round bottom plates at a density of 1  106 cells per well and incu-
bated at 37 C with 5% CO2 in media only, with γ-irradiated RB51 (1 
107 CFU/well), or with pokeweed mitogen (PWM, 4 μg/mL) (Sigma-Al-
drich, St. Louis, MO).
2.6. Surface marker staining
PBCM were prepared ex vivo for surface cell marker staining by
washing in PBS, followed by incubation with a fixable viability dye
(Invitrogen Molecular Probes/ThermoFisher) for 20 min at 4 C, fol-
lowed by a PBS wash step, and resuspension in FACS buffer (PBS with
0.5% FBS). Cells were incubated at room temperature (RT) with primary
antibodies for mouse anti-bovine CD3 (IgG1; Washington State Univer-
sity) and mouse anti-bovine CD45RO (IgG3; Bio-Rad, Hercules, CA), for
15 min, followed by BV421-labeled rat anti-mouse IgG1 (BD Biosciences,
San Jose, CA) and BUV395-labeled rat anti-mouse IgG3 (BD Biosciences)
for 15 min. After two wash steps in FACS buffer, cells were labeled with
FITC-labeled mouse anti-bovine CD4 (Bio-Rad), PE-Cy7-labeled rat anti-
human CCR7 (BD Bioscience), and PE-Cy5-labeled mouse anti-human
CD62L (Biolegend, San Diego, CA). After two additional wash steps in
FACS buffer, cells were resuspended in stabilizing fixative (BD Biosci-
ence). Data was collected using a FACS Aria II flow cytometer (BD Bio-
sciences) and analyzed using FlowJo® software (Tree Star, Inc., Ashland,
OR).
2.7. Intracellular cytokine staining (ICS)
To measure intracellular cytokine production, PBMC were treated
with a 1x solution of eBioscienceTM Protein Transport Inhibitor (Ther-
moFisher Scientific) overnight for 16 h prior to harvesting at 7 days post-
stimulation. Cells were washed twice with PBS, stained for viability and
surface markers as described above, and then fixed and permeabilized
using the BD Cytofix/CytopermTM kit (BD Biosciences), in accordance
with manufacturer's recommendations. Cells were then incubated with
PE-labeled mouse anti-bovine IFN-γ for 30 min at 4 C. After staining,
cells were washed and resuspended in stabilizing fixative (BD Biosci-
ence). Data was collected using a FACS Aria II flow cytometer (BD Bio-
sciences) and analyzed using FlowJo® software (Tree Star, Inc.).
2.8. RB51-specific IgG serum ELISA
Blood was collected into tiger top tubes and serum obtained by
centrifugation. Serum was stored at -20 C until analysis. Humoral IgG
responses to RB51 antigens were measured via enzyme-linked immu-
nosorbent assay (ELISA), as described previously (Olsen et al., 2009),
with some modifications. Briefly, 96-flat bottom plates were coated with
1  108 CFU of methanol-killed RB51 diluted in coating buffer (carbo-
nate-bicarbonate buffer, pH 9.6) and incubated overnight at 4 C.
Blocking of wells was performed using SuperBlock (ThermoFisher) in
accordance with manufacturer's recommendations. After washing 3
times with wash buffer (PBS with 0.05% Tween 20), serum samples were
added in triplicate to wells at dilutions of 1:800, 1:1600, and 1:3200 and
incubated at RT for 2 h. For titration curves, serum samples were assessed
in triplicates at dilutions of 1:1600, diluted 1:12,800, 1:25,600, and 1:51,
200.
Plates were washed and then incubated with peroxidase-conjugated
rabbit anti-bovine IgG (HþL) (Jackson Immunoresearch laboratories,
West Grove, PA; 1:25,000), rabbit anti-bovine IgG1, or rabbit anti-bovine
IgG2 (Bethyl Labs, Montgomery, TX; 1:50,000) for 1 h at RT. Following a
wash, plates were developed using the TMB Microwell Peroxidase Sub-
strate System (ThermoFisher) in accordance with manufacturer recom-
mendations. After incubation, the reaction was stopped with 0.18 M
solution of sulfuric acid and absorbance was measured at 450 nm using a
plate reader.
2.9. IgG avidity ELISA
ELISAs to measure avidity were performed as described above with
minor modifications. All samples were tested at 1:1,600 dilution, in
triplicate. After a wash step, samples were incubated with 3 M urea, 6 M
urea or wash buffer for 10 min at RT. Plates were then incubated with
peroxidase-conjugated rabbit anti-bovine IgG (HþL) (1:25,000, Jackson
Immunoresearch laboratories) for 1 h at RT, followed by a wash step.
Plates were then developed and measured as described above. Avidity
index was calculated by the ratio of absorbance values from the 3M and 6
M urea treatments to absorbance values from samples incubated in wash
buffer.
2.10. Cytokine quantification via AlphaLISA
Culture supernatants from PBMC were harvested 48 h post-
stimulation and stored at -80 C until analysis. AlphaLISA kits were uti-
lized to measure IFN-γ, IL-4, IL-10, and IL-17A according to manufac-
turer's recommendations (PerkinElmer, Waltham, MA).
2.11. Histology
At necropsy, sections of skin and subcutaneous tissue around the
implant site were obtained and fixed in neutral, buffered 10% formal-
dehyde, embedded in paraffin, sectioned at 5 μm, and stained with he-
matoxylin and eosin.
2.12. Statistics
Statistical analyses were performed using ordinary one-way ANOVA
with Bonferoni's multiple comparisons test to determine statistical dif-
ferences between treatment groups at each time point, for both cytokine
and titer data sets. We considered each time point to be an independent
experiment, as assays were run and data was collected at individual time
points throughout the experimental timeline. For pair-wise comparisons,
a Student's t-test was used to determine statistical significance between
groups. Area under the curve (AUC) values were calculated for all
experimental groups at each of the timepoints analyzed. Statistical
analysis for AUC values were performed using one-way ANOVA with
Bonferoni's multiple comparisons test. All statistical calculations and
analyses were performed using GraphPad Prism7 software (GraphPad,
San Diego, CA). A p-value of <0.05 was considered statistically-
significant.
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3. Results
3.1. VPEAR implant site reaction
Subcutaneous surgical implantation of the VPEAR in the cervical re-
gion elicited mild, temporary (<48hr) swelling in some animals. No
other clinical effects were observed during the course of the study.
3.2. Peripheral RB51-specific CD4þ T cell IFN-γ responses
It has been previously shown that in cattle, CD4þ T cells are the main
source of IFN-γ production following RB51 vaccination (Dorneles et al.,
2015). Therefore, we assessed the peripheral CD4þ T cell recall response
to RB51 from PBMC isolated at different time points during the study.
The gating strategy and representative dot plots for the data are shown in
Fig. 1A. Following vaccination, we observed a significant increase (p 
0.05) in the mean percentage of IFN-γ-producing CD4þ T cells in pe-
ripheral blood of RB51 vaccinates at 4, 8 and 16-weeks post-vaccination
(Fig. 1B, gray bars) compared to naïve and VPEAR-implanted animals. At
12 weeks post-vaccination, mean frequency of IFN-γ-producing CD4þ T
cells trended higher but did not vary significantly (p  0.05) in RB51
vaccinates as compared to VPEAR or naïve animals. Interestingly, we did
not observe any differences (p  0.05) in the mean frequencies of
IFN-γ-producing CD4þ T cells between VPEAR and naïve animals
(Fig. 1B, black and white bars). We speculated that the lack of a
measurable peripheral response in VPEAR-vaccinated animals could be
attributed to localization of killed antigen at the site of vaccination
and/or draining lymph node. Since we did not expect killed antigen to
disseminate systemically, we hypothesized that any responses present
would not be found peripherally, and furthermore, if a localized cellular
response were present, then a systemic stimulus (i.e. in vivo recall
response) may allow us to detect a memory response in circulation.
To test this hypothesis, we boosted all vaccinated animals with live
RB51 and measured peripheral CD4þ IFN-γ responses. Following booster,
the mean frequency of antigen-specific IFN-γ-producing CD4þ T cells in
PBMC begins to increase (p  0.05) by 2 weeks post-boost, but is
significantly increased (p  0.05) at 4 weeks after booster vaccination in
both VPEAR and RB51 groups compared to the naïve animals (Fig. 1C).
This response to RB51 boost was short-lived, as the mean percentage of
IFN-γ-producing CD4þ T cells was comparable (p  0.05) to naïve re-
sponses by 8 weeks after booster vaccination. The observed kinetics are
consistent with the profile of an anamnestic response to RB51, as they
occur much faster and are shorter lived when compared to the kinetics of
the primary response to RB51 vaccination (Fig. 1B). Altogether, these
data suggest that VPEAR-vaccinated animals can generate a memory,
IFN-γ-mediated CD4þ T cell response comparable to RB51 vaccination.
3.3. Assessment of memory CD4þ T cell subpopulations
To further characterize the memory CD4þ T cell response, we
Fig. 1. Assessment of peripheral RB51-specific, IFN-γ production by CD4þ T cells following VPEAR and RB51 vaccination and RB51 boost. (A) Representative dot
plots showing FSC vs. SSC profile, gating strategy for singlet discrimination, viability assessment, and CD4 and intracellular IFN-γ staining on bovine PBMC. Time
course showing the frequency of IFN-γþ CD4þ T cells in PBMC from naïve (open bars), VPEAR- (black bars) or RB51-vaccinated (gray bars) animals following (B)
initial vaccination and (C) post-RB51 boost. (D) Frequency of IFN-γþ CD4þ T cells in PBMC following stimulation with pokeweed mitogen as a positive control for IFN-
γ production. Lower-case letters denote statistical significance between treatment groups at each individual timepoint, indicated by a p value 0.05.
P.M. Boggiatto et al. Heliyon 5 (2019) e02370
4
assessed memory subpopulations in PBMC before and after RB51 booster
vaccination. We utilized CD45RO (a surface marker of memory T cells)
and a combination of CCR7 (a chemokine receptor) and CD62L (a cell
adhesion molecule) to distinguish between central memory (TCM, CCR7þ
CD62Lþ) and effector memory (TEM: CCR7þ CD62Llow) CD4þ T cells.
Fig. 2A demonstrates the gating strategy and representative dot plots for
the data. Overall, no differences (p  0.05) were found between VPEAR
and RB51 vaccinates at any of the time points or for any of the pop-
ulations analyzed (Fig. 2).
However, we did observe changes in the circulating frequencies of
memory subpopulations before and after RB51 boost. When compared to
pre-RB51 boost frequencies, both vaccinate groups showed an increased
frequency of total CD4þ T cells at 4 and 8 weeks post-boost (Fig. 2B).
Additionally, the mean percentage of CD45ROþ CD4þ memory T cells
(Fig. 2C) appears to increase by 2 weeks post-boost, but was then
decreased by 8 weeks post-boost. Within the circulating memory subset,
we observed an increase in the mean frequency of TCM cells (Fig. 2D) and
a decrease in the mean frequency of TEM (Fig. 2E) cells at 4 and 8 weeks
post-boost. As expected for a memory response, we did not observe an
increase in the mean frequency of CD4þ T cells with an effector pheno-
type (CD45RO CCR7- CD62L/low) (Fig. 2F). Overall, the kinetics of
memory CD4þ T cell subpopulations in both RB51 and VPEAR treatments
groups were similar following RB51 boost.
Fig. 2. Characterization of CD4þ T cell subpopulations in PBMC following RB51 immunological challenge of VPEAR- and RB51-vaccinated animals. (A) Top panels are
representative dot plots of PBMC analyzed ex vivo showing FSC vs. SSC profile and gating strategy for singlet discrimination and viability. Bottom panels are
representative dot plots showing staining profiles with and gating strategies for CD3, CD4, CD45RO, CCR7 and CD62L. Shown are the kinetics of (B) total CD4þ T cells,
(C) CD4þ memory T cells (CD45ROþ), (D) central memory CD4þ T cells (TCM: CD45RO
þ CCR7þ CD62Lþ), (E) effector memory CD4þ T cells (TEM: CD45RO
þ CCR7-
CD62L), and (F) effector CD4þ T cells (Teff: CD45RO CCR7- CD62L) in the peripheral blood of VPEAR- (black circles) and RB51-vaccinated (open circles) animals
following RB51 immunological challenge or boost.
P.M. Boggiatto et al. Heliyon 5 (2019) e02370
5
3.4. RB51-specific IgG titers
Compared to naïve and VPEAR groups, mean IgG responses to RB51
after initial vaccination were increased (p  0.05) at 4, 8, and 12 weeks
post-vaccination (Fig. 3A). In contrast, humoral responses of animals in
the VPEAR group did not differ (p  0.05) from naïve animals at any of
sampling times after initial vaccination.
As observed with CD4þ T cell responses, we speculated that the initial
vaccination with VPEAR was not sufficient to induce a measurable, pe-
ripheral IgG response. Therefore, we evaluated IgG responses after RB51
booster vaccination in bothVPEARand RB51 treatments. RB51-specific IgG
increased (p  0.05) at 4, 8, and 12 weeks post-RB51 boost in VPEAR and
RB51 treatments compared to naïve animals (Fig. 3B). Additionally, at 8
weeks post-boost, there is a significant difference (p 0.05) betweenmean
IgG responses in the VPEAR- compared to RB51-vaccinated animals after
booster vaccination. Titration curves were performed and area under the
curve (AUC) values were calculated for various timepoints following RB51
boost to assess the quality of the antibody response (Supplemental
Figure 2). Consistent with the above data, we observed statistically sig-
nificant differences between vaccinates and naïve animals (2, 8 and 12
weeks post-boost), and between VPEAR- and RB51-vaccinates animals at 8
weeks post-boost (Supplemental Table 1).
We also assessed the IgG isotypes following initial vaccination and
RB51 boost. At the time point analyzed, the predominant IgG isotype
within sera of vaccinates was IgG1 (Fig. 3C), regardless of vaccination
treatment.
3.5. Avidity of RB51-specific IgG responses
Previous work with this vaccination platform demonstrated an in-
crease in antibody avidity over time (Schaut et al., 2018a). When eval-
uated at 8 weeks post-vaccination and 8 weeks post-boost, all vaccination
Fig. 3. Assessment of RB51-specific IgG titers in serum from VPEAR and RB51 vaccinated animals following initial vaccination and RB51 boost. Time course of RB51-
specific total IgG in the serum of naïve (white bars), VPEAR- (black bars) and RB51-vaccinated (gray bars) animals at different time points following (A) initial
vaccination and (B) RB51 boost. (C) Assessment of RB51-specific IgG isotypes, IgG1 and IgG2 in serum at 8 weeks post-initial vaccination and 8 weeks post-RB51
boost. (D) Assessment of RB51-specific IgG avidity at 8 weeks post-initial vaccination and 8 weeks post-RB51 boost Lower-case letters denote statistical signifi-
cance between treatment groups at each individual timepoint, (*) denotes statistical significance as indicated by a p value 0.05.
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treatments demonstrated an expected loss of avidity with increasing
concentrations of the chaotropic agent. However, antibody avidity did
not differ (p  0.05) between vaccination treatments (Fig. 3D).
3.6. Histology of implant sites
At necropsy, 15 months after initial vaccination, the site of implan-
tation was grossly visible and palpable in all animals. Upon dissection,
the VPEAR implant and rod were located within the subcutaneous space
(Fig. 4A, top left), and grossly appeared surrounded by a fibrous capsule
(Fig. 4A, top right and bottom left). Histologically, tissue immediately
adjacent to the PVDF membrane cap of the implant demonstrated
marked, moderately congested, radially oriented vascularization sepa-
rated by streams of active, large fibroblasts in a collagen matrix (Fig. 4B).
Variably sized islands of plasma cells were present within the central cap
(Fig. 4B, C and D) accompanied frequently by hemosiderin pigment
(Fig. 4D).
Surrounding the polymer rod were islands of moderate numbers of
epithelioid macrophages with pronounced lymphocytic aggregates
(Fig. 4E and F) interspersed within large streams of collagen fibers.
Multinucleated giant cells were frequently observed stretching thinly
around the polymer (Fig. 4G) and very large macrophages were found in
the area of the rod appeared very large. Moderate numbers of eosinophils
were also present (Fig. 4H). Rings of macrophages containing randomly
dispersed eosinophils and small aggregates of lymphocytes encircled the
rod (Fig. 4G). This was further surrounded by a halo of collagen bundles.
4. Discussion
The work presented in this manuscript characterizes the immune
response elicited by a polyanhydride-based vaccination platform for
extended antigen release in cattle and compares the immunologic re-
sponses to those elicited by vaccination with live RB51. The vaccine
design is based on the phenomenon of concomitant immunity or non-
sterile immunity (Coffman et al., 2010; Perignon and Druilhe, 1994;
Smith et al., 1999). This phenomenon was mimicked by providing a
three-hit model of antigen availability to the host: (1) soluble antigen, (2)
a fast-eroding antigen-containing PA rod, and (3) a slow-eroding, anti-
gen-containing PA rod and diffusion barrier. The dynamics of antigen
presentation to the host via this platformwould imitate a bolus of antigen
availability after initial infection, followed by a slower release of antigen
over a 3-month period and lastly, a slow release of antigen passively
regulated by the formation of antigen-antibody complexes and hindered
diffusion. We propose that altogether, this model would not only extend
antigen release, it would mimic the dynamics of a persistent infection
(i.e. controlled antigen release regulated by the immune response itself)
without inducing tolerance to the antigen.
The VPEAR, PA rod and the polyethylene implant, was well tolerated
as no clinical (i.e. swelling, drainage) or histologic evidence of adverse
reactions were noted through the course of the study. An interesting
finding was the observation of a large number of plasma cells adjacent to
the implant cap, which was previously reported (Schaut et al., 2018a). To
our knowledge, plasma cells are not typically recruited to the site of
vaccination, suggesting this may be a unique feature of this vaccination
platform and may be indicative of antibody production at the interphase
between the host and the implant. This site was also characterized by a
highly vascularized structure, suggesting active communication between
the implant and the host at this interface. Notably, these findings are
reminiscent of tertiary lymphoid structures, which can be induced by
chronic immune stimulation. Tertiary lymphoid structures play an
important role in the priming and maintenance of T and B cell responses
in both inflammatory and infectious conditions (reviewed in (Neyt et al.,
2012)). It would be of interest to further explore the dynamic interactions
occurring at the site of implantation, and characterize the nature of the
observed lymphoid aggregates at this site.
Immune responses after the initial placement of the VPEAR were very
limited. In contrast, conventional vaccination with live RB51 induced
peripheral, antigen-specific IFN-γ-producing CD4þ T cell responses,
Fig. 4. Gross and histological images of implant and implant site. (A) Gross appearance of the implant and rod in the subcutaneous space (top left); appearance of
implant on cut surface and connection of tissue at the PVDF membrane (top right, black arrow, and bottom left); and appearance of the rod on cut surface (bottom
right). (B) Representative histology of the PVDF membrane cap site with radially-oriented vascularization separated by streams of fibroblasts and collagen (black
dashed arrows) and multiple lymphocytic islands (dashed square). (C) Close up of lymphocytic island showing aggregates of plasma cells. (D) 80 image of plasma
cells within cap site (red arrows) and hemosiderin pigment present throughout (black arrow heads). (E–H) Representative histology of the area surrounding the
polymer rod (*), surrounded by islands of lymphocytes (dashed red circle), dense collagen (purple arrow), multinucleate giant cells (black arrow) and numerous
eosinophils (red arrow heads).
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measurable between 8-12 weeks and peaking at 16 weeks post-
vaccination (Fig. 1A). The lack of CD4þ T cell responses in the VPEAR
treatment could be explained by: (1) the killed RB51 antigen was not a
sufficient amount to elicit a cellular response; (2) the cellular response
was not of the TH1 type (i.e. TH2, TH17, Treg/IL-10 mediated); (3) or the
response was localized around the implant or within the draining lymph
node. Therefore, we boosted all vaccinated animals with RB51 to test the
hypothesis that VPEAR initiated and sustained an antigen-specific im-
mune response in vivo.
Following RB51 boost, in both VPEAR- and RB51-vaccinated animals,
the peak response was observed between 2-4 weeks post-boost, much
earlier than with initial vaccination (8–16 weeks). This early response is
consistent with an anamnestic rather than a primary response to antigen,
suggesting that VPEAR- and RB51-vacinated animals had memory CD4þ
T cells capable of producing IFN-γ in response to RB51 boost. Similar to a
previous report (Dorneles et al., 2015), following RB51 boost, we did not
observe any measurable levels of IL-4 in culture supernatants in either
vaccinate group (data not shown). Additionally, we measured IFN-γ,
IL-10 and IL-17A at 2- and 4- weeks post-boost in culture supernatants,
and observed no differences between the two vaccinate groups (Sup-
plemental Figure 1). Altogether, these data demonstrate that the memory
responses elicited by RB51 boost are similar between the two vaccinate
groups.
Despite a lack of a measurable response after initial vaccination with
VPEAR, there is a measurable anamnestic response, and similar to that
observed in RB51-vaccinated animals. These data would support the
hypothesis that VPEAR is capable of priming a RB51-specific, IFN-
γ-mediated, CD4þ T cell response in cattle. Previous work by Vitry et al.
showed that in the mouse, the presence of IFN-γ-producing CD4þ TH1
cells requires immunization with live Brucella (Vitry et al., 2014). His-
torically, successful vaccines against brucellosis have been live attenu-
ated strains as heat-killed or subcellular fractions fail to provide the same
level of protection (Olsen, 2013). However, in our study, the magnitude
and kinetics of the IFN-γ-mediated, CD4þ T cell memory response of
VPEAR-vaccinated animals is very similar to the memory response of
RB51-vaccinated animals, following boost. Our data suggest that with
this vaccine platform, it may be possible to elicit and sustain cellular
responses against killed Brucella antigens without developing tolerance.
However, it remains to be determined whether these cellular responses
would be protective against challenge with field strains of B. abortus.
In an attempt to further characterize the kinetics of the secondary
CD4þ T cell response induced following RB51 boost, we analyzed the
frequency of memory subpopulations in circulation. Overall, we did not
observe any significant differences in any of the populations analyzed
between VPEAR and RB51-vaccinated animals (Fig. 2). The magnitude
and kinetics of memory CD4þ T cell subpopulations following boost with
RB51 appear very similar between the vaccinate groups, suggesting that
both vaccines are capable of inducing TEM and TCM, which are known to
be important for protection. Unfortunately, little is known regarding the
memory T cell subsets that provide immunological protection against
Brucella infection in cattle. Further understanding of memory sub-
populations and their functional phenotypes that confer protection
against Brucella are critical as we move forward with the development of
this and other vaccine formulations against brucellosis.
Similar to the kinetics of the CD4þ T cell response, an RB51-specific
IgG response could not be detected following initial VPEAR vaccina-
tion. Animals vaccinated with RB51 showed an increase in RB51-specific
IgG as early at 4 weeks post-vaccination, with decreasing titers by 16
weeks (Fig. 3), as previously reported (Olsen et al., 1999). As expected for
an anamnestic response, following the RB51 boost, RB51-vaccinated
animals respond by showing a significant increase in mean IgG titers.
Interestingly, after RB51 boost, titers in VPEAR-vaccinated animals
trended to be higher as compared to RB51-vaccinated animals, and were
sustained out to 12 weeks post-boost. Again, these kinetics and magni-
tude are consistent with an anamnestic rather than a naïve response to
RB51. We speculate that similar to the cellular responses, initial humoral
responses to VPEAR may have remained localized to the site of implan-
tation and/or lymph node. Histology data showing the recruitment of
plasma cells to the implant cap support the localization of humoral re-
sponses to the vaccine site. Altogether, the data demonstrate that VPEAR
is capable of initiating and sustaining humoral responses to killed RB51
antigen similar to live RB51.
Schaut et al. showed that in the mouse, this vaccine platform can
maintain anti-GnRH antibody levels and enhances antibody avidity
(Schaut et al., 2018a). While we did observe sustained anti-RB51 anti-
body titers following RB51 boost in the VPEAR- and RB51-vaccinated
animals, we did not observe any differences in antibody avidity at the
time point analyzed (8 weeks post vaccination and 8 weeks post-RB51
boost). This could be attributed to the nature of the antigen used be-
tween the two studies: purified protein vs. multiple antigenic peptide.
Nevertheless, VPEAR and RB51 appear to have similar avidity indices at
the timepoint analyzed.
The data presented here show that killed antigen could potentially be
utilized to generate IFN-γ-mediated, CD4þ T cell responses and humoral
responses against Brucella abortus in its natural host. The rationale behind
the design was to mimic the kinetics of antigen availability during
persistent infections, which result in the development of concomitant
immunity. To our knowledge, this novel approach to vaccination against
persistent infections, such as Brucella, has not been attempted before.
Further characterization of the observed cellular and humoral memory
responses is warranted, along with studies to determine if vaccination
with this platform can provide protection against challenge with field
strains of B. abortus.
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